Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955358 | 1.00 | ERCC5 (0.53) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL27023278 | 0.92 | ERCC5 (0.51) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL30335736 | 0.86 | ERCC5 (0.61) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL853580 | 0.86 | ERCC5 (0.61) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL11582804 | 0.85 | KLKB1 (0.44) | ERCC5FEN1KMT2ALMNAMEN1 | |
| SCHEMBL15979733 | 0.85 | CES2 (0.62) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL15778916 | 0.83 | TSHR (0.49) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL16893390 | 0.82 | TSHR (0.46) | ERCC5FEN1KMT2ALMNAKDM4E | |
| SCHEMBL15979722 | 0.81 | CTNNB1 (0.60) | KMT2ARAB9APOLBCES2CES1 | |
| SCHEMBL11581372 | 0.81 | LMNA (0.56) | KMT2ALMNAKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-111278809-B | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3704097-B1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | GENENTECH, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3704097-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| CN-111278809-A | Bicyclic sulfones and sulfoxides, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072617-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | ERCC5 1753/4885FEN1 3657/4885KMT2A 855/4885 |
| US-20190127382-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | ERCC5 1753/4885FEN1 3657/4885KMT2A 855/4885 |
| US-12338241-B2 | Bicyclic sulfones and sulfoxides and methods of use thereof | RB1, CCNE2, RPS3A | ERCC5 1753/4885FEN1 3657/4885KMT2A 855/4885 |
| US-20230002391-A1 | BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF | RB1, CCNE2, RPS3A | ERCC5 1753/4885FEN1 3657/4885KMT2A 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.